Trials / Completed
CompletedNCT00961766
Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the safety/tolerability profile, systemic PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BG00010 (Neublastin) | Single dose, weight-based IV administration |
| DRUG | Placebo | Single dose IV matched placebo |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2009-08-19
- Last updated
- 2014-10-28
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00961766. Inclusion in this directory is not an endorsement.